“…Pulmonary arterial hypertension (PAH), characterized by mean pulmonary artery pressure (mPAP) ≥ 25 mmHg at rest, pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and pulmonary vascular resistance (PVR) > 3 Wood units [ 1 ], is a disease induced by a wide range of causes, which makes it difficult to formulate an appropriate therapeutic plan and receive great responses for PAH patients [ 2 ]. Up till the present, most patients can only rely on combined targeted medicine, however, not all patients can be relieved [ 2 , 3 ]. Besides, the 1-year, 3-year and 5-year survival rate of medium to high-risk patients treated by target therapy are 90%, 61%, 43% [ 4 ], and side effects of targeted medicine are not tolerable in a considerable number of patients.…”